|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Evolving roles of magnifying endoscopy and endoscopic resection for neoplasia in inflammatory bowel diseases显示文摘Magnifying endoscopy is a useful technique to differentiate neoplasia from non-neoplastic lesions. Data regarding the clinical utility of magnifying endoscopy for neoplasia in patients with inflammatory bowel disease(IBD) has been emerging.While Kudo’s pit pattern types Ⅲ-Ⅴ are findings suggestive of neoplasia in non-IBD patients, these pit patterns are predictive of IBD-associated neoplasia as well.However, active chronic inflammatory processes, particularly regenerative changes, can mimic neoplastic pit patterns and may affect a meticulous evaluation of pit pattern diagnosis in patients with IBD. The clinical evidence regarding the utility of magnifying endoscopy with narrow band imaging or endocytoscopy has also been evolving in regard to the diagnosis of IBD-associated neoplasia. These advanced endoscopic techniques are promising for multiple reasons;not only for making an accurate diagnosis of neoplasia, but also in determining if endoscopic resection is appropriate for such lesions in patients with IBD. In this review, we discuss the diagnostic accuracy and limitations of magnifying endoscopy in assessing IBD-associated neoplasia and examine the feasibility and outcomes of endoscopic resection for these lesions. | Shintaro Akiyama Taku Sakamoto Joshua M Steinberg Yutaka Saito Kiichiro Tsuchiya | 2022 | World Journal of Gastrointestinal Oncology2022，14，3： | 2 |
| 2 | Synthesis and biological evaluation of loxoprofen derivatives显示文摘 | NAOKI Y SHINTARO S MASAAKI M | 2011 | Bioorg Med Chem2011，19，11： | 1 |
| 3 | Wireless strain monitoring using electrical capacitance change of tire:part Ⅰ-with oscillating circuit显示文摘 | Akira T Shintaro M Yoshinobu S | 2003 | Smart Mater Struct2003，12，3： | 1 |
| 4 | Study on Sludge Formation during the Oxidation Process of Turbine Oils显示文摘 | AKIHIKO Y SHINTARO W YASUNORI M | 2004 | Tribology Transactions2004，47，1： | 1 |
| 5 | Wireless strain monitoring using electrical capacitance change of tire:part Ⅱ-passive显示文摘 | Akira T Shintaro M Yoshinobu S | 2003 | Smart Mater Struct2003，12，3： | 1 |
| 6 | Systemic Candidiasis and Mesenteric Mast Cell Tumor with Multiple Metastases in a Dog 显示文摘 | Kazuya M Kanako S Shintaro K | 2009 | J Vet Med Sci2009，71，2： | 1 |
| 7 | Elastase inhibition reduced death associated with acid aspiration-induced lung injury in hamsters显示文摘 | Tetsuya H Shigeru M Shintaro N | 2004 | European Journal of Pharmacology2004，488，： | 1 |
| 8 | Feasibility of chitosan-based hyaluronic acid hybrid biomaterial for a novel scaffold in cartilage tissue engineering显示文摘 | NORIMASA I TOKIFUMI M | 2005 | Biomaterials2005，26，： | 1 |
| 9 | Characteristics of inflammatory bowel diseases in patients with concurrent immune-mediated inflammatory diseases显示文摘Patients with inflammatory bowel disease(IBD)are more likely to have concurrent immune-mediated inflammatory diseases(IMIDs)than those without IBD.IMIDs have been observed to alter the phenotype and outcomes of IBD in recent studies.Several studies have found that IBD patients with concurrent IMIDs may have more extensive or severe disease phenotypes,and are considered to be at increased risk of requiring biologics and IBD-related surgeries,suggesting that having multiple IMIDs is a poor prognostic factor for IBD.Furthermore,IBD patients with primary sclerosing cholangitis and Takayasu arteritis are reported to have unique endoscopic phenotypes,suggesting concurrent IMIDs can influence IBD phenotype with specific intestinal inflammatory distributions.In this review,we discuss the pathogenesis,disease phenotypes,and clinical outcomes in IBD patients with concomitant IMIDs. | Shintaro Akiyama Soma Fukuda Joshua M Steinberg Hideo Suzuki Kiichiro Tsuchiya | 2022 | World Journal of Gastroenterology2022，28，25： | 0 |
| 10 | Pregnancy and medications for inflammatory bowel disease:An updated narrative review显示文摘Inflammatory bowel disease(IBD)is often diagnosed during the peak reprodu-ctive years of young women.Women with active IBD around conception are at a significantly increased risk of disease relapse during pregnancy,which is associated with poor pregnancy and neonatal outcomes.Given these substantial risks,it is prudent that disease remission should ideally be achieved before conception.Unfortunately,some patients may experience a disease flare-up even if they are in a state of remission before pregnancy.Patients must continue their IBD medications to reduce the risk of disease flare and subsequent poor outcomes during the gestational and postpartum periods.When treating IBD flare-ups during pregnancy,the management is quite similar to the therapeutic approach for non-pregnant patients with IBD,including 5-aminosalicylate,steroids,calcineurin inhibitors(CNIs),and biologic therapies.While the data regarding the safety of CNIs in pregnant women with IBD is limited,the findings in our recent meta-analysis suggest that CNIs may be safer to use in those with IBD than in solid organ transplant recipients.There are several types of biologics and small-molecule therapies currently approved for IBD,and physicians should thoroughly understand their clinical benefits and safety profiles when utilizing these treatments in the context of pregnancy.This review highlights recent studies,including our systematic review and meta-analysis,and discusses the clinical advantages and safety considerations of biologics and small molecules for pregnant women with IBD. | Shintaro Akiyama Joshua M Steinberg Mariko Kobayashi Hideo Suzuki Kiichiro Tsuchiya | 2023 | World Journal of Clinical Cases2023，11，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员